Literature DB >> 23337370

Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?

Dirk Roggenbuck, Dimitrios Bogdanos, Karsten Conrad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23337370     DOI： 10.1016/j.crohns.2012.12.013

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

1.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

2.  Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.

Authors:  Martin W Laass; Nadja Röber; Ursula Range; Lydia Noß; Dirk Roggenbuck; Karsten Conrad
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

3.  The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.

Authors:  Valentina Somma; Hani Ababneh; Ahmad Ababneh; Simona Gatti; Vittorio Romagnoli; Emanuele Bendia; Karsten Conrad; Dimitrios P Bogdanos; Dirk Roggenbuck; Gino Ciarrocchi
Journal:  Gastroenterol Res Pract       Date:  2013-05-15       Impact factor: 2.260

Review 4.  CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.

Authors:  Christos Liaskos; Eirini I Rigopoulou; Timoklia Orfanidou; Dimitrios P Bogdanos; Christos N Papandreou
Journal:  Clin Dev Immunol       Date:  2013-04-22

5.  Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Gary L Norman; Malgorzata Milkiewicz; Marcin Krawczyk; Chelsea Bentow; Zakera Shums; Michael Mahler; Steffi Lopens; Dirk Reinhold; Andre Franke; Christoph Schramm; Dirk Roggenbuck; Piotr Milkiewicz
Journal:  Aliment Pharmacol Ther       Date:  2020-11-07       Impact factor: 8.171
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.